Cytomedix, Inc. Logo

Cytomedix to Host Conference Call on Friday, December 21 to Discuss CMS Preliminary Decision of Non-Coverage of PRP Gel

Print
| Source: Cytomedix, Inc.

ROCKVILLE, Md., Dec. 21, 2007 (PRIME NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF) announced that it will host a conference call today, Friday, Dec. 21 at 1:00 p.m. Eastern time. Dr. Kshitij Mohan, Chairman and CEO, will discuss the preliminary decision announced yesterday by the Centers for Medicare and Medicaid Services (CMS) to reaffirm its 2003 national non-coverage decision for autologous blood derived products for treating chronic non-healing wounds, including the Company's AutoloGel(tm) System.

To participate, dial 1-877-407-8035 approximately 10 minutes before the conference call is scheduled to begin. Hold for the operator and reference the Cytomedix, Inc. conference call. International callers should dial 201-689-8035.

Access to a recording will also be available for seven days following the conference call. Dial 1-877-660-6853 to access playback. For international callers, dial 201-612-7415. Enter account number 286. The conference I.D. is 267277.

ABOUT CYTOMEDIX

Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for uses in the treatment of wounds and other applications. The current offering is AutoloGel(tm), an FDA cleared treatment that utilizes an autologous platelet gel composed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.

Cytomedix, Inc.
Kshitij Mohan, Ph.D., Chairman and CEO
(240) 499-2680

The Wall Street Group, Inc.
Ron Stabiner
(212) 888-4848